BIOMARKERS AND METHOD FOR PREDICTION OR PROGNOSIS OF THE RESPONSE TO TREATMENT WITH BRAF INHIBITORS AND MEK INHIBITORS (BRAFI + MEKI)

• Main Authors: CASTELLÓN RUBIO, Victoria Eugenia, BERCIANO GUERRERO, Miguel Ángel, NAVAS DELGADO, Ismael, TOSCANO MURILLO, Fátima, ONIEVA ZAFRA, Juan Luis, HENAO CARRASCO, Fernando, MOYA GARCÍA, Aurelio Ángel, LAVADO VALENZUELA, María del Rocío, SANCHO MÁRQUEZ, María Pilar, RUEDA DOMÍNGUEZ, Antonio, ALBA CONEJO, Emilio, VALDIVIA BAUTISTA, Javier, DE LA CRUZ MERINO, Luis, MONTESA PINO, Álvaro
• Format: Patent
• Language: English; French; Spanish
• Published: 07.07.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

Disclosed are: biomarkers and a method for the prediction or prognosis of the response to treatment with BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) in patients with mutated BRAF metastatic melanoma; a kit or device; and the uses thereof. Biomarcadores y método para predecir o pronosticar la respuesta al tratamiento con inhibidores de BRAF y de MEK (BRAFi + MEKi) de los pacientes que padecen melanoma metastásico BRAF mutado, kit o dispositivo y usos. L'invention concerne des biomarqueurs et un procédé de prédiction ou de pronostic de la réponse au traitement avec des inhibiteurs de BRAF et de MEK (BRAFi + MEKi) de patients souffrant de mélanome métastasique BRAF muté, un kit ou un dispositif et leurs utilisations.